Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis

Chemistry and Biology

Volumn 22, Issue 9, 2015, Pages 1206-1216

  Hiraki, Masatsugu ^a   Hwang, So Young ^a   Cao, Shugeng ^b,c   Ramadhar, Timothy R ^c   Byun, Sanguine ^a   Yoon, Kyoung Wan ^a   Lee, Jung Hyun ^a   Chu, Kiki ^a   Gurkar, Aditi U ^a   Kolev, Vihren ^a   Zhang, Jianming ^a   Namba, Takushi ^a   Murphy, Maureen E ^d   Newman, David J ^e   Mandinova, Anna ^a,f   Clardy, Jon ^c   Lee, Sam W ^a,f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF HAWAII AT HILO   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d WISTAR INSTITUTE   (United States)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHETOMIN; HEAT SHOCK PROTEIN 40; MUTANT PROTEIN; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; DISULFIDE; DNAJB1 PROTEIN, HUMAN; INDOLE ALKALOID; MOLECULAR LIBRARY; TP53 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MOLECULE; MOUSE; MUTANT; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; REGULATORY MECHANISM; SQUAMOUS CELL CARCINOMA; TONGUE CANCER; ANIMAL; CHEMISTRY; DRUG SCREENING; GENETICS; HCT 116 CELL LINE; HIGH THROUGHPUT SCREENING; METABOLISM; MOLECULAR LIBRARY; MUTATION; NUDE MOUSE; PHARMACOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISULFIDES; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HSP40 HEAT-SHOCK PROTEINS; HUMANS; INDOLE ALKALOIDS; MICE; MICE, NUDE; MUTATION; SMALL MOLECULE LIBRARIES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941935599     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2015.07.016     Document Type: Article

References (46)

1. M.A. Allen, Z. Andrysik, V.L. Dengler, H.S. Mellert, A. Guarnieri, J.A. Freeman, K.D. Sullivan, M.D. Galbraith, X. Luo, W.L. Kraus, and et al. Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms Elife 3 2014 e02200
2. M.L. Avantaggiati, V. Ogryzko, K. Gardner, A. Giordano, A.S. Levine, and K. Kelly Recruitment of p300/CBP in p53-dependent signal pathways Cell 89 1997 1175 1184
3. G.J. Bates, S.M. Nicol, B.J. Wilson, A.M. Jacobs, J.C. Bourdon, J. Wardrop, D.J. Gregory, D.P. Lane, N.D. Perkins, and F.V. Fuller-Pace The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor EMBO J. 24 2005 543 553
4. A.N. Bullock, and A.R. Fersht Rescuing the function of mutant p53 Nat. Rev. Cancer 1 2001 68 76
5. F. Bunz, A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J.P. Brown, J.M. Sedivy, K.W. Kinzler, and B. Vogelstein Requirement for p53 and p21 to sustain G2 arrest after DNA damage Science 282 1998 1497 1501
6. V.J. Bykov, N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, P. Chumakov, J. Bergman, K.G. Wiman, and G. Selivanova Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound Nat. Med. 8 2002 282 288
7. V.J. Bykov, N. Issaeva, N. Zache, A. Shilov, M. Hultcrantz, J. Bergman, G. Selivanova, and K.G. Wiman Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs J. Biol. Chem. 280 2005 30384 30391
8. J.-D. Chai, and M. Head-Gordon Long-range corrected hybrid density functionals with damped atom-atom dispersion corrections Phys. Chem. Chem. Phys. 10 2008 6615 6620
9. F. Chen, W. Wang, and W.S. El-Deiry Current strategies to target p53 in cancer Biochem. Pharmacol. 80 2010 724 730
10. F. Cherblanc, Y.P. Lo, E. De Gussem, L. Alcazar-Fuoli, E. Bignell, Y. He, N. Chapman-Rothe, P. Bultinck, W.A. Herrebout, R. Brown, and et al. On the determination of the stereochemistry of semisynthetic natural product analogues using chiroptical spectroscopy: desulfurization of epidithiodioxopiperazine fungal metabolites Chem. Eur. J. 17 2011 11868 11875
11. K.M. Cook, S.T. Hilton, J. Mecinovic, W.B. Motherwell, W.D. Figg, and C.J. Schofield Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism J. Biol. Chem. 284 2009 26831 26838
12. B.A. Foster, H.A. Coffey, M.J. Morin, and F. Rastinejad Pharmacological rescue of mutant p53 conformation and function Science 286 1999 2507 2510
13. H. Fujimoto, S. Megumi, E. Okuyama, and M. Ishibashi Immunomodulatory constituents from an ascomycete, Chaetomium seminudum J. Nat. Prod. 67 2004 98 102
14. C. Gaiddon, M. Lokshin, J. Ahn, T. Zhang, and C. Prives A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain Mol. Cell. Biol. 21 2001 1874 1887
15. T.C. He, S. Zhou, L.T. da Costa, J. Yu, K.W. Kinzler, and B. Vogelstein A simplified system for generating recombinant adenoviruses Proc. Natl. Acad. Sci. USA 95 1998 2509 2514
16. K.K. Hoe, C.S. Verma, and D.P. Lane Drugging the p53 pathway: understanding the route to clinical efficacy Nat. Rev. Drug Discov. 13 2014 217 236
17. B. Hong, V.V. Prabhu, S. Zhang, A.P. van den Heuvel, D.T. Dicker, L. Kopelovich, and W.S. El-Deiry Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53 Cancer Res. 74 2014 1153 1165
18. A.C. Joerger, and A.R. Fersht Structural biology of the tumor suppressor p53 Annu. Rev. Biochem. 77 2008 557 582
19. J. Kessler, A. Hahnel, H. Wichmann, S. Rot, M. Kappler, M. Bache, and D. Vordermark HIF-1alpha inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression BMC Cancer 10 2010 605
20. F.W. King, A. Wawrzynow, J. Hohfeld, and M. Zylicz Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53 EMBO J. 20 2001 6297 6305
21. A.L. Kung, S.D. Zabludoff, D.S. France, S.J. Freedman, E.A. Tanner, A. Vieira, S. Cornell-Kennon, J. Lee, B. Wang, J. Wang, and et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway Cancer Cell 6 2004 33 43
22. D.P. Lane Cancer. p53, guardian of the genome Nature 358 1992 15 16
23. M.S. Lawrence, P. Stojanov, C.H. Mermel, J.T. Robinson, L.A. Garraway, T.R. Golub, M. Meyerson, S.B. Gabriel, E.S. Lander, and G. Getz Discovery and saturation analysis of cancer genes across 21 tumour types Nature 505 2014 495 501
24. D. Lee, J.W. Kim, T. Seo, S.G. Hwang, E.J. Choi, and J. Choe SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription J. Biol. Chem. 277 2002 22330 22337
25. B. Leroy, J.L. Fournier, C. Ishioka, P. Monti, A. Inga, G. Fronza, and T. Soussi The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis Nucleic Acids Res. 41 2013 D962 D969
26. A.J. Levine, and M. Oren The first 30 years of p53: growing ever more complex Nat. Rev. Cancer 9 2009 749 758
27. A. Mandinova, and S.W. Lee The p53 pathway as a target in cancer therapeutics: obstacles and promise Sci. Transl. Med. 3 2011 64rv61
28. P.A. Muller, and K.H. Vousden Mutant p53 in cancer: new functions and therapeutic opportunities Cancer Cell 25 2014 304 317
29. F. Murray-Zmijewski, D.P. Lane, and J.C. Bourdon p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress Cell Death Differ. 13 2006 962 972
30. T. Namba, F. Tian, K. Chu, S.Y. Hwang, K.W. Yoon, S. Byun, M. Hiraki, A. Mandinova, and S.W. Lee CDIP1-BAP31 complex transduces apoptotic signals from endoplasmic reticulum to mitochondria under endoplasmic reticulum stress Cell Rep. 5 2013 331 339
31. T. Okamoto, H. Izumi, T. Imamura, H. Takano, T. Ise, T. Uchiumi, M. Kuwano, and K. Kohno Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression Oncogene 19 2000 6194 6202
32. L. Raj, T. Ide, A.U. Gurkar, M. Foley, M. Schenone, X. Li, N.J. Tolliday, T.R. Golub, S.A. Carr, A.F. Shamji, and et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS Nature 475 2011 231 234
33. A. Rehman, M.S. Chahal, X. Tang, J.E. Bruce, Y. Pommier, and S.S. Daoud Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells Breast Cancer Res. 7 2005 R765 R774
34. N. Rokaeus, G. Klein, K.G. Wiman, L. Szekely, and K. Mattsson PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins Oncogene 26 2007 982 992
35. M.F.N. Rosser, and D.M. Cyr Do Hsp40s act as chaperones or co-chaperones? Chapter 4 G.L. Blatch, Networking of Chaperones by Co-Chaperones 2007 Springer 38 51
36. S. Sjogren, M. Inganas, T. Norberg, A. Lindgren, H. Nordgren, L. Holmberg, and J. Bergh The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry J. Natl. Cancer Inst. 88 1996 173 182
37. A. Staab, J. Loeffler, H.M. Said, D. Diehlmann, A. Katzer, M. Beyer, M. Fleischer, F. Schwab, K. Baier, H. Einsele, and et al. Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells BMC Cancer 7 2007 213
38. U. Stelzl, U. Worm, M. Lalowski, C. Haenig, F.H. Brembeck, H. Goehler, M. Stroedicke, M. Zenkner, A. Schoenherr, S. Koeppen, and et al. A human protein-protein interaction network: a resource for annotating the proteome Cell 122 2005 957 968
39. K. Sugito, M. Yamane, H. Hattori, Y. Hayashi, I. Tohnai, M. Ueda, N. Tsuchida, and K. Ohtsuka Interaction between hsp70 and hsp40, eukaryotic homologues of DnaK and DnaJ, in human cells expressing mutant-type p53 FEBS Lett. 358 1995 161 164
40. K. Takada, D. Zhu, G.H. Bird, K. Sukhdeo, J.J. Zhao, M. Mani, M. Lemieux, D.E. Carrasco, J. Ryan, D. Horst, and et al. Targeted disruption of the BCL9/beta-catenin complex inhibits oncogenic Wnt signaling Sci. Transl. Med. 4 2012 148ra117
41. S.A. Waksman, and E. Bugie Chaetomin, a new antibiotic substance produced by Chaetomium cochliodes: I. Formation and properties J. Bacteriol. 48 1944 527 530
42. C.D. Wassman, R. Baronio, O. Demir, B.D. Wallentine, C.K. Chen, L.V. Hall, F. Salehi, D.W. Lin, B.P. Chung, G.W. Hatfield, and et al. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53 Nat. Commun. 4 2013 1407
43. A. Willis, E.J. Jung, T. Wakefield, and X. Chen Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes Oncogene 23 2004 2330 2338
44. J. Yu, L. Zhang, P.M. Hwang, K.W. Kinzler, and B. Vogelstein PUMA induces the rapid apoptosis of colorectal cancer cells Mol. Cell 7 2001 673 682
45. X. Yu, A. Vazquez, A.J. Levine, and D.R. Carpizo Allele-specific p53 mutant reactivation Cancer Cell 21 2012 614 625
46. Z. Yuan, A. Villagra, L. Peng, D. Coppola, M. Glozak, E.M. Sotomayor, J. Chen, W.S. Lane, and E. Seto The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions Mol. Cell. Biol. 30 2010 3004 3015